甾体盐皮质激素受体拮抗剂在需要透析的肾衰竭患者中的安全性和有效性:随机对照试验的系统综述与Meta分析
该系统综述与Meta分析更新了既往综述,检索截至2025年3月18日的随机对照试验,纳入19项试验共4675例维持性透析患者,评估甾体盐皮质激素受体拮抗剂的心血管死亡率等结局。在4项低偏倚风险试验(n=3562)中,心血管死亡风险比值为OR 0.98(95%CI 0.80-1.20),绝对风险降低为每1000患者年减少1例事件(95%CI 减少14例至增加11例),证据确定性为中等。作者认为甾体盐皮质激素受体拮抗剂对透析患者心血管死亡率几乎无影响。
要点
- 在低偏倚风险试验中,甾体盐皮质激素受体拮抗剂组心血管死亡264/1785例,对照组276/1777例,OR 0.98(95%CI 0.80-1.20),无显著差异。
- 绝对风险降低为每1000患者年减少1例事件(95%CI 减少14例至增加11例),证据确定性为中等。
- 作者认为甾体盐皮质激素受体拮抗剂对透析患者心血管死亡率几乎无影响,非甾体盐皮质激素受体拮抗剂无相关信息。
核心结论
- 作者认为甾体盐皮质激素受体拮抗剂对需要透析的患者心血管死亡率几乎无影响。
- 关于甾体盐皮质激素受体拮抗剂在透析患者亚组中的效应信息不足,且无非甾体盐皮质激素受体拮抗剂的信息。
- 未来试验设计需考虑效应可能较小或仅限于盐皮质激素驱动病理生理更明确的事件或患者。
研究设计与样本
- 系统综述与Meta分析,更新既往系统综述,检索MEDLINE、Embase、Cochrane Central Register of Controlled Trials和Cumulative Index to Nursing and Allied Health Literature,检索时间从数据库建库至2025年3月18日。
- 纳入比较盐皮质激素受体拮抗剂与安慰剂或标准治疗的随机对照试验,対象为接受维持性透析的成人(年龄≥18岁)。
- 排除未报告感兴趣结局(心血管死亡率、心力衰竭住院、全因死亡率、全因住院、高钾血症、男性乳房发育或乳房疼痛、低血压)的研究。
- 两位评价者独立筛选研究、提取数据并使用Cochrane偏倚风险工具评估偏倚风险;主要结局为心血管死亡率,采用经验贝叶斯随机效应模型,按偏倚风险分层。
- 方案在PROSPERO注册(CRD420251008119);共纳入19项甾体盐皮质激素受体拮抗剂试验,包括4675例参与者。
主要发现
- 在4项低偏倚风险试验(n=3562)中,盐皮质激素受体拮抗剂组1785例患者发生264例心血管死亡,对照组1777例患者发生276例心血管死亡,OR 0.98(95%CI 0.80-1.20);I²=0.0%;τ²=0.0;证据确定性为中等。
- 绝对风险降低为每1000患者年减少1例事件(95%CI 减少14例至增加11例)。
关键数值与推荐
- 低偏倚风险试验中心血管死亡:盐皮质激素受体拮抗剂组264/1785例 vs 对照组276/1777例,OR 0.98(95%CI 0.80-1.20),无显著差异。
- 绝对风险降低:每1000患者年减少1例事件(95%CI 减少14例至增加11例)。
- 异质性:I²=0.0%;τ²=0.0;证据确定性为中等。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出,关于甾体盐皮质激素受体拮抗剂在需要透析的患者亚组中的效应信息不足。
- 作者指出,目前没有关于非甾体盐皮质激素受体拮抗剂的信息。
- 作者指出,未来试验设计需考虑效应可能较小或仅限于盐皮质激素驱动病理生理更明确的事件或患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but their effects in patients with kidney failure requiring dialysis are uncertain. We aimed to assess the efficacy and safety of mineralocorticoid receptor antagonists in this patient population. METHODS: In this systematic review and meta-analysis, we updated our previous systematic review by searching MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and the Cumulative Index to Nursing and Allied Health Literature for randomised controlled trials published between database inception and March 18, 2025. Trials comparing a mineralocorticoid receptor antagonist with placebo or standard of care in adults (aged ≥18 years) receiving maintenance dialysis were eligible. Studies that did not report an outcome of interest (cardiovascular mortality, heart failure hospitalisation, all-cause mortality, all-cause hospitalisation, hyperkalaemia, gynaecomastia or breast pain, or hypotension) were excluded. Two reviewers independently identified studies, extracted data, and assessed the risk of bias using the Cochrane risk-of-bias tool. The main outcome was cardiovascular mortality assessed using the empirical Bayes random-effects models, stratified by risk-of-bias. The protocol is registered with PROSPERO (CRD420251008119). FINDINGS: 19 trials of steroidal mineralocorticoid receptor antagonists including 4675 participants met eligibility criteria. Effect estimates differed trials with low and high risk of bias. In four trials with a low risk of bias (n=3562), 264 cardiovascular deaths occurred in 1785 patients in the mineralocorticoid receptor antagonist group compared with 276 of 1777 patients in the control group (odds ratio 0·98 [95% CI 0·80-1·20]; I2=0·0%; τ2=0·0; moderate certainty) resulting in an absolute risk reduction of 1 fewer event per 1000 patients per year (95% CI 14 fewer to 11 more). INTERPRETATION: Our findings suggest that steroidal mineralocorticoid receptor antagonists have little to no effect on cardiovascular mortality in patients requiring dialysis. There is insufficient information on the effects of steroidal mineralocorticoid receptor antagonists in subgroups of patients requiring dialysis and no information on non-steroidal mineralocorticoid receptor antagonists. Future trials would need to consider the likelihood of only smaller effects or effects limited to patients or events with pathophysiology that is more clearly driven by aldosterone in their design. FUNDING: None.
引用
- Pyne L, Rossignol P, Giles C, et al. Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2025. PMID: 40840478. doi:10.1016/S0140-6736(25)01153-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。